Project Grant R21HL173856
Award Date 8/1/24
Completion Date 7/31/26
Dollars Obligated $451K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- This $740,338 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of Protease Activated Receptor 2 (PAR2) in the initiation and progression of abdominal aortic aneurysms (AAAs). The research aims to determine how PAR2 expression and activity in vascular smooth muscle cells may impact the structural integrity of the aortic wall and contribute to AAA...
- This $274,547 Project Grant awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program aims to develop a novel Aneurysm Sealing Device (ASD) for endovascular treatment of Abdominal Aortic Aneurysms (AAA). The project seeks to create a device that can completely seal the aneurysm sac, reducing the risk of post-procedure complications and the need for repeat interventions. Key objectives include validating the device's adaptability...
- This federal Project Grant award of $686,685 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to study the genetic and epigenetic factors that influence the development of abdominal aortic aneurysms (AAA) related to tobacco use. The primary awardee, The Leland Stanford Junior University, will leverage its expertise in vascular biology and genetic research to develop an innovative mouse model of chronic tobacco-induced AAA. The...
- This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Aneurisk, Inc. to develop and validate machine learning models for risk classification, growth projection, and wall stress prediction for abdominal aortic aneurysms (AAA). The project aims to create an artificial intelligence-based clinical decision support tool that enables clinicians to improve the treatment of patients with...
- This $713,382 Project Grant award from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research at the University of Pennsylvania on the role of triglyceride-rich lipoproteins in the growth and progression of abdominal aortic aneurysms. The research aims to generate definitive causal evidence on how triglyceride-rich lipoproteins influence the development, growth, and rupture of these life-threatening aortic aneurysms, with the goal...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will provide $377,520 to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, to conduct research on the characterization of ENTPD1 as a potential drug target for the treatment of pseudoxanthoma elasticum (PXE). The research will focus on improving understanding of how the...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $445,500 supports research to define the mechanisms by which platelets may regulate monocyte/macrophage interactions at the site of abdominal aortic aneurysm (AAA) injury, with the goal of developing new tools to promote tissue regeneration and healing of cardiovascular damaged tissues. The research aims to provide a blueprint for site-specific regeneration and healing of AAAs, which...
- This $367,577 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to Adepthera LLC aims to develop a regenerative peptide therapy to accelerate pressure ulcer healing. Specifically, the award will fund research to identify an optimal formulation of a self-assembling adrenomedullin (ADM) analog gel that can improve local blood circulation and wound healing in aging and diabetic mouse models. The proposed therapy would be administered weekly or biweekly via...
- This $440,000 Project Grant award from the National Eye Institute (NEI), under Federal Grant Program 93.867 (Vision Research), aims to develop a novel, disease-targeted anti-angiogenic therapy for treating wet age-related macular degeneration (AMD). The key product being developed is a neutralizing monoclonal antibody that targets a new, CNV-selective angiogenic factor discovered through the awardee's comparative ligandomics technology. This approach differs from currently approved anti-VEGF...
- The National Eye Institute (NEI), under the federal Vision Research grant program (CFDA 93.867), awarded a $300,016 project grant to Fannin Partners LLC, a Houston-based biomedical research company, to develop SCG3 raptamers as a novel targeted therapy for wet age-related macular degeneration (AMD). Wet AMD is a leading cause of vision loss, affecting over 1.25 million individuals in the United States. The project aims to create an aptamer-based treatment that targets secretogranin III (SCG3), a...